First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Joaquim Bellmunt, Lei Pang et al.|The Lancet Oncology|2017

Cited by 1.3k